enGene Therapeutics Inc.
ENGNFigures shown here come from public SEC filings. Dates beside each section show the available history.
How enGene Therapeutics Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Oct 31, 2025. The latest insider filing shown is dated Jun 17, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among enGene Therapeutics Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-10-30 · Forbion Growth Opportunities Fund I Cooperatief U.A.: Larger than all 14 other insider purchases of Common Shares on file. SEC filing
- 2024-09-30 · Forbion Growth Opportunities Fund I Cooperatief U.A.: Larger than 13 of the 14 other insider purchases of Common Shares on file. SEC filing
Independent insiders buying near the same time
- 2024-09-27–2024-10-04: 8 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2024-10-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +561,797 | 8.90 | SEC filing |
| 2024-10-08 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +800 | 6.60 | SEC filing |
| 2024-10-07 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +11,844 | 6.55 | SEC filing |
| 2024-10-04 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +5,997 | 6.54 | SEC filing |
| 2024-10-03 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +5,769 | 6.48 | SEC filing |
| 2024-10-02 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +10,153 | 6.37 | SEC filing |
| 2024-10-01 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +35,279 | 6.44 | SEC filing |
| 2024-09-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. · 10% owner | Common Shares | P — Open market or private purchase | +341,332 | 6.34 | SEC filing |
Showing 8 of 13 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-16 | HASTINGS PAUL J · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-16 | Glickman Richard M · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-16 | Zoth Lota S. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-16 | Grossman William · Interim Chief Medical Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +200,000 | SEC filing |
| 2026-06-16 | Astley-Sparke Philip · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-16 | Joustra Wouter · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-16 | Heffernan Michael Thomas · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
| 2026-06-16 | Grossman William · Interim Chief Medical Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +31,000 | SEC filing |
Showing 8 of 14 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2023-10-31 | Forbion Growth Sponsor FEAC I B.V. · 10% owner | Warrant (Right to Buy) | J — Other acquisition or disposition | +950,153 | SEC filing |
| 2023-10-31 | Forbion Growth Sponsor FEAC I B.V. · 10% owner | Warrant (Right to Buy) | J — Other acquisition or disposition | +54,634 | SEC filing |
| 2023-10-31 | Forbion Growth Sponsor FEAC I B.V. · 10% owner | Class A Common Stock | J — Other acquisition or disposition | +130,085 | SEC filing |
| 2023-10-31 | Forbion Growth Sponsor FEAC I B.V. · 10% owner | Class A Common Stock | J — Other acquisition or disposition | +2,262,351 | SEC filing |
Showing 4 of 4 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.